CASE STUDY

Successful Launch of Notch Therapeutics



Notch is an immune cell therapy company developing universal, off-the-shelf T cell therapies derived from renewable stem cell sources.



Sourced Technologies Identified and bundled promising technologies from academic institutions. Built Program Generated Proof of Concept (PoC) data and strategically selected therapeutic

indications.

Spun-Out Company ted external partnersh

Created external partnerships, attracted experienced leadership and raised seed funding.

THE NOTCH THERAPEUTICS STORY

1 Bundling of Technologies and IP protection

CCRM identified promising technologies from two academic labs and led in filing Intellectual Property (IP). CCRM hired student inventor to continue developing IP.

Company Ideation

CCRM developed the business plan based on market and competitor landscape, and secured an entrepreneur-in-residence with a track record of success.

Company Launch

CCRM co-founded the company with academic institutions and facilitated licensing of the technology to newly formed Notch Therapeutics.

Internal Development

CCRM validated the technology and designed PoC studies to demonstrate therapeutic utility.

External Partnerships and Funding

CCRM worked to develop strategic partnerships and built relationships with investors.

Continued Infrastructure and Manufacturing Support

CCRM designed a comprehensive support strategy, including ongoing lab contract services.

LAUNCHING YOUR INNOVATIONS INTO THE CLINIC



INCUBATING **AND LAUNCHING NEW COMPANIES: OUR PROCESS**

With over 1,000 consultation hours and more than 360 technology reviews completed, CCRM's commercialization expertise will enable you to streamline the processes required to bring your inventions to market.

CCRM NETWORK AND

KEY OPINION LEADERS

EXTERNAL VENTURES, STRATEGIC PARTNERS, **ACADEMIC INVENTIONS**

Bundle technologies

Validation and guidance

ACADEMIC INVENTIONS

AND DISCOVERIES

-0-

GENERATE

& CREATE

CCRM'S INTERNAL IDEAS AND INNOVATIONS

Source

technologies

development and ideation

WE ARE

100+ Employees >70% w/ Advanced Degrees

Process Development and Scale up (CATCT) and cGMP Facility (CCVP)

Specialized R&D **Reprogramming and Gene Editing**

Academic, Industry and Investor **Networks**

9 Portfolio companies **CAD\$600M+** Raised to-date

Y

